SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS), a small-cap biotechnology company currently valued at $72 million, has seen its stock decline 86% over the past year. According to a recent SEC filing, Director Gerhard Prante has sold shares of the company’s Class A common stock. InvestingPro analysis suggests the stock is trading below its Fair Value despite recent volatility. On January 14, Prante sold 1,150 shares at a price of $2.42 per share, totaling approximately $2,783. Following this transaction, Prante holds 42,207 shares directly.
The sale was executed under a pre-established Rule 10b5-1 trading plan, which was adopted on August 16, 2024. This type of plan allows insiders to set up a predetermined schedule for buying or selling stock to avoid any potential conflicts of interest or accusations of insider trading.
In other recent news, Cibus Inc., a leader in agricultural gene editing, has been making significant strides despite a net loss of $201.5 million. The company has reported a significant revenue growth of over 440% in the last twelve months, and the Compensation Committee of Cibus’s Board of Directors has approved a new base salary of $320,000 for executive Carlo Broos. Jefferies, an investment firm, has adjusted its price target for Cibus, reducing it to $5.00 while maintaining a Hold rating on the stock.
Cibus anticipates earning $200 million annually in royalties from rice traits in the U.S. and an additional $150 million from expansion into Asian markets. The company is also planning to launch herbicide-resistant and Pod Shatter Reduction traits, targeting significant market opportunities in the U.S., Latin America, and Asia.
Cibus’s path to reaching free cash flow is contingent upon the successful development of either a soy or wheat trait, or the ability to get its product across 2 to 5 million acres. In partnership with Albaugh, Cibus aims to aid in herbicide labeling in Latin America. The company is also exploring sustainable ingredients and fragrances, with announcements expected in the future. These recent developments reflect Cibus’s ongoing efforts to enhance agricultural productivity and sustainability through gene editing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
